>북미 탄저균 치료 시장, 유형별( 피부 탄저균 , 폐 탄저균 및 장 탄저균), 투여 경로(경구, 비경구 및 기타), 최종 사용자(정부 기관, 병원, 학술 및 연구 기관 및 기타)별 산업 동향 및 2029년까지의 전망.
북미 탄저균 치료 시장 분석 및 통찰력
북미 탄저균 치료 시장은 박테리아 감염 발생률 증가 , 연구 자금 증가, 탄저균 치료 및 파이프라인 제품에 대한 새로운 치료법 개발과 같은 요인에 의해 주도되고 있으며, 수요도 증가하고 있으며, 연구 개발에 대한 투자 증가로 시장이 성장하고 있습니다. 현재 선진국과 신흥국에서 의료비 지출이 증가하여 제조업체가 새롭고 혁신적인 제품을 개발할 수 있는 경쟁 우위를 확보할 것으로 예상됩니다.
전 세계적으로 탄저병에 걸린 사람의 수가 증가하면서 탄저병 치료 시장이 성장하는 주요 요인 중 하나가 되었습니다. 연구자들이 새로운 개입법을 개발하기 위한 재정 지원이 증가하고, 민간인과 군대 사이에서 탄저균에 노출될 위험이 증가하면서 시장 성장이 가속화되었습니다. 연구 개발 프로그램의 수가 증가하고, 혁신적이고 효과적인 치료를 위한 새로운 개발을 촉진하기 위한 공공-민간 파트너십이 증가하면서 시장에 더 많은 영향을 미쳤습니다. 그러나 치료 및 시술과 관련된 높은 비용과 제품 승인을 위한 엄격한 정부 규정이 탄저병 치료 시장 성장을 방해할 것으로 예상됩니다.
북미 탄저균 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
북미 탄저균 치료 시장은 지지적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 북미 탄저균 치료 시장이 2022년에서 2029년까지의 예측 기간 동안 4.2%의 CAGR로 성장할 것이라고 분석합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029 |
|
Countries Covered |
U.S., Canada, Mexico |
|
Market Players Covered |
Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., BlueWillow Biologics., Altimmune, among others |
North America Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the North America anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the North America market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the North America anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
North America Anthrax Treatment Market Segmentation
North America anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the North America anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, North America anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, North America anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
The North America anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are U.S., Canada and Mexico.
The U.S.is expected to dominate due to increasing technological advancement in the developing areas.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 탄저균 치료 시장 점유율 분석
북미 탄저균 치료 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 북미 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 회사의 탄저균 치료 시장에 대한 초점과만 관련이 있습니다.
시장의 일부 주요 기업으로는 Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., BlueWillow Biologics, Altimmune 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 NORTH AMERICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 NORTH AMERICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 NORTH AMERICA VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 46 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 47 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 48 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 49 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 52 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 53 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 54 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 55 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 NORTH AMERICA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 63 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 64 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 67 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 68 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 70 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 73 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 74 NORTH AMERICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 79 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 82 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 83 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 84 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 85 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 88 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 89 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 90 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 91 U.S. ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 92 U.S. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 94 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 95 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 96 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 U.S. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 99 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 100 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 101 U.S. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 102 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 103 U.S. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 106 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 107 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 108 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 109 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 110 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 112 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 113 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 114 U.S. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 115 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 116 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 117 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 118 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 119 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 120 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 121 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 122 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 123 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 124 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 125 U.S. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 126 U.S. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 127 CANADA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 128 CANADA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 129 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 130 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 131 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 132 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 133 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 134 CANADA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 135 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 136 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 137 CANADA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 138 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 139 CANADA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 140 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 141 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 142 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 143 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 144 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 145 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 146 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 147 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 148 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 149 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 150 CANADA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 151 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 152 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 153 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 154 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 155 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 156 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 157 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 158 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 159 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 160 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 161 CANADA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 162 CANADA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 163 MEXICO ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 164 MEXICO CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 165 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 166 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 167 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 168 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 169 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 170 MEXICO BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 171 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 172 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 173 MEXICO VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 174 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 175 MEXICO PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 176 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 177 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 178 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 179 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 180 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 181 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 182 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 183 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 184 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 185 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 186 MEXICO INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 187 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 188 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 189 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 190 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 191 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 192 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 193 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 194 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 195 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 196 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 197 MEXICO ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 198 MEXICO ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 NORTH AMERICA DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA ANTHRAX TREATMENT MARKET
FIGURE 21 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
